Table 2.

Ongoing or recently completed Chinese clinical trials with MSCs/MSC-sEVs in COVID-19.

Clinical trial registration	Study title	Status	Phase	Patients	MSC type	Dose and infusion
NCT04252118	MSCs treatment for pneumonia patients infected with COVID-19	Recruiting	I	20	HucMSCs	Conventional treatment plus 3 times of 3.0 × 107 MSCs intravenously at day 0, day 3, and day 6
NCT04339660	Clinical research of human MSCs in the treatment of COVID-19 pneumonia	Recruiting	I/II	30	HucMSCs	1 × 106 MSCs/kg body weight suspended in 100 ml saline intravenously
NCT04346368	BMMSCs treatment for severe patients with coronavirus disease 2019 (COVID-19)	Not yet recruiting	I/II	20	HBMSCs	Conventional treatment plus 1 × 106/kg body weight MSCs intravenously at day 1
NCT04273646	Study of hucMSCs in the treatment of severe COVID-19	Not yet recruiting	Not applicable	48	HucMSCs	4 times of 0.5 × 106/kg body weight MSCs intravenously at day 1, day 3, day 5, and day 7
NCT04288102	Treatment with hucMSCs for severe corona virus disease 2019 (COVID-19)	Completed	II	45	HucMSCs	3 doses of 4.0 × 107 MSCs intravenously at day 0, day 3, and day 6
NCT04276987	A pilot clinical study on inhalation of MSC sEVs treating severe novel coronavirus pneumonia	Completed	I	24	HADSC- sEVs	5 times aerosol inhalation of 2.0 × 108 MSC-sEVs/3 ml at day 1, day 2, day 3, day 4, and day 5
NCT04371601	Safety and effectiveness of MSCs in the treatment of pneumonia of coronavirus disease 2019	Active, not recruiting	I	60	HucMSCs	Conventional treatment plus 1 × 106/kg body weight MSCs once every 4 days for a total of 4 times intravenously within 3 days of first admission
NCT04269525	HucMSCs treatment for the 2019-novel coronavirus (nCOV) pneumonia	Recruiting	II	16	HucMSCs	3.3 × 107 MSCs/50 ml/bag, 3 bags each time, 1 time each day, infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment